Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-1471a in Advanced Solid Tumors
NCT06074705Phase 1Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2023
- Primary completion
- Jul 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of DS-1471a in solid tumor (advanced stage) (9 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of Participants With Dose-limiting Toxicities and Number of Participants With Treatment-emergent Adverse Events. Started Aug 2023; status: terminated.
02
Drugs
DS-1471a
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06074705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06074705.